Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
AssigneeNovartis AG
InventorsMatthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
Claims62
A method of treating prostate cancer and/or a metastasis thereof, comprising administering to a patient a therapeutically effective amount of a compound of the formula:
- and/or a salt thereof,
- wherein R′ is a chelator of the formula:
- wherein a radionuclide is complexed to the chelator.
A method of treating prostate cancer and/or a metastasis thereof, comprising administering to a patient a therapeutically effective amount of a composition comprising:
- (1) a compound of the formula:
- and/or a salt thereof,
- wherein R′ is a chelator of the formula:
- wherein a radionuclide is complexed to the chelator, and
- (2) optionally a pharmaceutically acceptable carrier.
A method of treating prostate cancer and/or a metastasis thereof, comprising administering to a patient a therapeutically effective amount of a compound of the formula:
- and/or a salt thereof,
- wherein R′ is a chelator of the formula:
- wherein a radionuclide is complexed to the chelator.
A method of treating prostate cancer and/or a metastasis thereof, comprising administering to a patient a therapeutically effective amount of a composition comprising:
- (1) a compound of the formula:
- and/or a salt thereof,
- wherein R′ is a chelator of the formula:
- wherein a radionuclide is complexed to the chelator, and
- (2) optionally a pharmaceutically acceptable carrier.
A method of treating prostate cancer and/or a metastasis thereof, comprising administering to a patient a therapeutically effective amount of a compound of the formula:
- and/or a salt thereof,
- wherein R′ is a chelator of the formula:
- wherein a radionuclide is complexed to the chelator.
A method of treating prostate cancer and/or a metastasis thereof, comprising administering to a patient a therapeutically effective amount of a composition comprising:
- (1) a compound of the formula:
- and/or a salt thereof,
- wherein R′ is a chelator of the formula:
- wherein a radionuclide is complexed to the chelator, and
- (2) optionally a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.